News | November 15, 2024
Emraclidine was well-tolerated with an adverse event profile consistent with Phase 1b trial
We are witnessing a steady and sustainable growth in the country as the Q2 revenue from operations increased by 31%
This includes $2 billion of new investment creating more than a thousand new, high-skilled jobs
Real-world and long-term extension data, including updated results from post-launch evaluation of REMS Program, bolster growing body of evidence supporting the efficacy and safety profile of CAMZYOS
Net Profit was at Rs. 10.04 crore, as compared to Rs. 5.12 crore in Q2 FY24, clocking a growth of 96.22%
Pharma CDMO business has posted a 40% YoY in Q2 driven by BD efforts and backed by macro tailwinds
He specializes in financial planning, audit, compliance and ERP implementation, with extensive experience in leading automation and risk management projects
In Q2 FY25, our crop protection segment reported revenue of Rs. 159 crore, with an EBIT margin of 5%
Subscribe To Our Newsletter & Stay Updated
